

United States Senate

WASHINGTON, DC 20510

December 12, 2024

Jay Higham
Chief Executive Officer, Behavioral Health Group
5001 Spring Valley Road, Suite 600E
Dallas, TX 75244

Dear Mr. Higham:

On March 12, 2024, we wrote to you about methadone for Opioid Use Disorder (OUD) and posed ten questions about private-equity investment in your Opioid Treatment Provider (OTP). We are grateful for your response. But your response failed to respond to the specific questions that our letter posed. We set them forth again below and request your written responses by January 10, 2025:

1. Please provide a comprehensive overview of any current or previous private equity investment in your OTP, including the date of the investment, the geographic location(s) of the investment, the name(s) of the private equity firm(s) involved, and a summary of the non-confidential terms and conditions of the investment. Please also provide any term sheet.
2. If there is any private equity investment in your OTP, what specific objectives or goals were outlined in the agreement between the OTP and the private equity firm(s)? How have these objectives been tracked and measured over time?
3. What is the total amount of capital that the private equity firm(s) invested in your OTP, if any? How has this investment been allocated within the OTP, and what key areas or projects have received funding as a result of the private equity investment?
4. Please provide an overview of the financial performance and profitability of the OTP before and after any private equity investment. Please include relevant financial metrics and any changes in revenue, expenses, or profit margins.
5. Has your OTP made any modifications to the criteria or guidelines for prescribing or dispensing methadone since any private equity investment? If so, please identify them.
6. Since any private equity investment, has there been any involvement by the PE firm(s) in any decisions regarding clinical practices? If so, please describe that involvement.
7. Since any private equity investment, have there been any updates or enhancements to the training programs provided to OTP staff involved in methadone prescribing and dispensing? If so, please describe them.

8. Has any private equity investment influenced patient education and counseling regarding methadone usage, potential side effects, and associated risks? If so, how?

9. Please provide data on patient outcomes specifically related to methadone treatment, both pre- and post- any private equity investment, including data on key performance indicators related to patient success rates, relapse rates, and overall satisfaction. Have there been any notable improvements or challenges in patient outcomes linked to methadone treatment since the involvement of private equity?

10. How has any private equity investment affected the OTP's compliance with state and federal regulations governing the use of methadone in opioid treatment programs? Are there any specific challenges or successes related to regulatory compliance that can be attributed to the private equity investment?

Thank you in advance for your attention to these requests.

Sincerely,



Edward J. Markey
United States Senator



Mike Braun
United States Senator

United States Senate

WASHINGTON, DC 20510

December 12, 2024

Mark Hickman
President & Chief Executive Officer, Western Pacific Med Corp
4544 San Fernando Road, Suite 202
Glendale, CA 91204

Mr. Hickman:

On March 12, 2024, we wrote to you about methadone for Opioid Use Disorder (OUD) and posed ten questions about private-equity investment in your Opioid Treatment Provider (OTP). We are grateful for your response. But your response failed to respond to the specific questions that our letter posed. We set them forth again below and request your written responses by January 10, 2025:

1. Please provide a comprehensive overview of any current or previous private equity investment in your OTP, including the date of the investment, the geographic location(s) of the investment, the name(s) of the private equity firm(s) involved, and a summary of the non-confidential terms and conditions of the investment. Please also provide any term sheet.
2. If there is any private equity investment in your OTP, what specific objectives or goals were outlined in the agreement between the OTP and the private equity firm(s)? How have these objectives been tracked and measured over time?
3. What is the total amount of capital that the private equity firm(s) invested in your OTP, if any? How has this investment been allocated within the OTP, and what key areas or projects have received funding as a result of the private equity investment?
4. Please provide an overview of the financial performance and profitability of the OTP before and after any private equity investment. Please include relevant financial metrics and any changes in revenue, expenses, or profit margins.
5. Has your OTP made any modifications to the criteria or guidelines for prescribing or dispensing methadone since any private equity investment? If so, please identify them.
6. Since any private equity investment, has there been any involvement by the PE firm(s) in any decisions regarding clinical practices? If so, please describe that involvement.
7. Since any private equity investment, have there been any updates or enhancements to the training programs provided to OTP staff involved in methadone prescribing and dispensing? If so, please describe them.

8. Has any private equity investment influenced patient education and counseling regarding methadone usage, potential side effects, and associated risks? If so, how?

9. Please provide data on patient outcomes specifically related to methadone treatment, both pre- and post- any private equity investment, including data on key performance indicators related to patient success rates, relapse rates, and overall satisfaction. Have there been any notable improvements or challenges in patient outcomes linked to methadone treatment since the involvement of private equity?

10. How has any private equity investment affected the OTP's compliance with state and federal regulations governing the use of methadone in opioid treatment programs? Are there any specific challenges or successes related to regulatory compliance that can be attributed to the private equity investment?

Thank you in advance for your attention to these requests.

Sincerely,



Edward J. Markey
United States Senator



Mike Braun
United States Senator

United States Senate

WASHINGTON, DC 20510

December 12, 2024

David K. White, PhD
Chief Executive Officer, BayMark Health Services
1720 Lakepoint Drive, Suite 117
Lewisville, TX 75057

Dear Dr. White:

On March 12, 2024, we wrote to you about methadone for Opioid Use Disorder (OUD) and posed ten questions about private-equity investment in your Opioid Treatment Provider (OTP). We are grateful for your response. But your response failed to respond to the specific questions that our letter posed. We set them forth again below and request your written responses by January 10, 2025:

1. Please provide a comprehensive overview of any current or previous private equity investment in your OTP, including the date of the investment, the geographic location(s) of the investment, the name(s) of the private equity firm(s) involved, and a summary of the non-confidential terms and conditions of the investment. Please also provide any term sheet.
2. If there is any private equity investment in your OTP, what specific objectives or goals were outlined in the agreement between the OTP and the private equity firm(s)? How have these objectives been tracked and measured over time?
3. What is the total amount of capital that the private equity firm(s) invested in your OTP, if any? How has this investment been allocated within the OTP, and what key areas or projects have received funding as a result of the private equity investment?
4. Please provide an overview of the financial performance and profitability of the OTP before and after any private equity investment. Please include relevant financial metrics and any changes in revenue, expenses, or profit margins.
5. Has your OTP made any modifications to the criteria or guidelines for prescribing or dispensing methadone since any private equity investment? If so, please identify them.
6. Since any private equity investment, has there been any involvement by the PE firm(s) in any decisions regarding clinical practices? If so, please describe that involvement.
7. Since any private equity investment, have there been any updates or enhancements to the training programs provided to OTP staff involved in methadone prescribing and dispensing? If so, please describe them.

8. Has any private equity investment influenced patient education and counseling regarding methadone usage, potential side effects, and associated risks? If so, how?

9. Please provide data on patient outcomes specifically related to methadone treatment, both pre- and post- any private equity investment, including data on key performance indicators related to patient success rates, relapse rates, and overall satisfaction. Have there been any notable improvements or challenges in patient outcomes linked to methadone treatment since the involvement of private equity?

10. How has any private equity investment affected the OTP's compliance with state and federal regulations governing the use of methadone in opioid treatment programs? Are there any specific challenges or successes related to regulatory compliance that can be attributed to the private equity investment?

Thank you in advance for your attention to these requests.

Sincerely,



Edward J. Markey
United States Senator



Mike Braun
United States Senator

United States Senate

WASHINGTON, DC 20510

December 12, 2024

Jim Shaheen
Chief Executive Officer, New Season
2500 Maitland Center Parkway, Suite 250
Maitland, FL 32751

Mr. Shaheen:

On March 12, 2024, we wrote to you about methadone for Opioid Use Disorder (OUD) and posed ten questions about private-equity investment in your Opioid Treatment Provider (OTP). We are grateful for your response. But your response failed to respond to the specific questions that our letter posed. We set them forth again below and request your written responses by January 10, 2025:

1. Please provide a comprehensive overview of any current or previous private equity investment in your OTP, including the date of the investment, the geographic location(s) of the investment, the name(s) of the private equity firm(s) involved, and a summary of the non-confidential terms and conditions of the investment. Please also provide any term sheet.
2. If there is any private equity investment in your OTP, what specific objectives or goals were outlined in the agreement between the OTP and the private equity firm(s)? How have these objectives been tracked and measured over time?
3. What is the total amount of capital that the private equity firm(s) invested in your OTP, if any? How has this investment been allocated within the OTP, and what key areas or projects have received funding as a result of the private equity investment?
4. Please provide an overview of the financial performance and profitability of the OTP before and after any private equity investment. Please include relevant financial metrics and any changes in revenue, expenses, or profit margins.
5. Has your OTP made any modifications to the criteria or guidelines for prescribing or dispensing methadone since any private equity investment? If so, please identify them.
6. Since any private equity investment, has there been any involvement by the PE firm(s) in any decisions regarding clinical practices? If so, please describe that involvement.
7. Since any private equity investment, have there been any updates or enhancements to the training programs provided to OTP staff involved in methadone prescribing and dispensing? If so, please describe them.


8. Has any private equity investment influenced patient education and counseling regarding methadone usage, potential side effects, and associated risks? If so, how?

9. Please provide data on patient outcomes specifically related to methadone treatment, both pre- and post- any private equity investment, including data on key performance indicators related to patient success rates, relapse rates, and overall satisfaction. Have there been any notable improvements or challenges in patient outcomes linked to methadone treatment since the involvement of private equity?

10. How has any private equity investment affected the OTP's compliance with state and federal regulations governing the use of methadone in opioid treatment programs? Are there any specific challenges or successes related to regulatory compliance that can be attributed to the private equity investment?

Thank you in advance for your attention to these requests.

Sincerely,



Edward J. Markey
United States Senator



Mike Braun
United States Senator

United States Senate

WASHINGTON, DC 20510

December 12, 2024

Dr. Rupert McCormac, IV
Founder and Chief Executive Officer, Crossroads Treatment Centers
200 East Broad Street, Suite 300
Greenville, SC 29601

Dear Dr. McCormac:

On March 12, 2024, we wrote to you about methadone for Opioid Use Disorder (OUD) and posed ten questions about private-equity investment in your Opioid Treatment Provider (OTP). We are grateful for your response. But your response failed to respond to the specific questions that our letter posed. We set them forth again below and request your written responses by January 10, 2025:

1. Please provide a comprehensive overview of any current or previous private equity investment in your OTP, including the date of the investment, the geographic location(s) of the investment, the name(s) of the private equity firm(s) involved, and a summary of the non-confidential terms and conditions of the investment. Please also provide any term sheet.
2. If there is any private equity investment in your OTP, what specific objectives or goals were outlined in the agreement between the OTP and the private equity firm(s)? How have these objectives been tracked and measured over time?
3. What is the total amount of capital that the private equity firm(s) invested in your OTP, if any? How has this investment been allocated within the OTP, and what key areas or projects have received funding as a result of the private equity investment?
4. Please provide an overview of the financial performance and profitability of the OTP before and after any private equity investment. Please include relevant financial metrics and any changes in revenue, expenses, or profit margins.
5. Has your OTP made any modifications to the criteria or guidelines for prescribing or dispensing methadone since any private equity investment? If so, please identify them.
6. Since any private equity investment, has there been any involvement by the PE firm(s) in any decisions regarding clinical practices? If so, please describe that involvement.
7. Since any private equity investment, have there been any updates or enhancements to the training programs provided to OTP staff involved in methadone prescribing and dispensing? If so, please describe them.

8. Has any private equity investment influenced patient education and counseling regarding methadone usage, potential side effects, and associated risks? If so, how?
9. Please provide data on patient outcomes specifically related to methadone treatment, both pre- and post- any private equity investment, including data on key performance indicators related to patient success rates, relapse rates, and overall satisfaction. Have there been any notable improvements or challenges in patient outcomes linked to methadone treatment since the involvement of private equity?
10. How has any private equity investment affected the OTP's compliance with state and federal regulations governing the use of methadone in opioid treatment programs? Are there any specific challenges or successes related to regulatory compliance that can be attributed to the private equity investment?

Thank you in advance for your attention to these requests.

Sincerely,



Edward J. Markey
United States Senator



Mike Braun
United States Senator